Sparlon Skin Reaction Safety Study Is Unlikely To Erase Need For Black Box
Executive Summary
Labeling for Sparlon for attention deficit/hyperactivity disorder will likely carry a black box warning for severe dermatological reactions even if Cephalon conducts an additional safety study to obtain approval
You may also be interested in...
FDA Rejects Sparlon Due To Single SJS Case; An Ominous Sign For Pharma?
FDA's decision that Cephalon's attention deficit hyperactivity disorder treatment Sparlon is not approvable - based on an adverse event in a single patient - could be indicative of a more challenging regulatory environment for manufacturers
FDA Rejects Sparlon Due To Single SJS Case; An Ominous Sign For Pharma?
FDA's decision that Cephalon's attention deficit hyperactivity disorder treatment Sparlon is not approvable - based on an adverse event in a single patient - could be indicative of a more challenging regulatory environment for manufacturers
Sparlon Is In Strattera Stratum With Regard To Efficacy, Committee Says
Efficacy of Cephalon's attention deficit/hyperactivity disorder drug Sparlon should be considered to be in the range of Lilly's Strattera, FDA's Psychopharmacologic Drugs Advisory Committee said March 23